+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Castleman Disease Treatment Market (2021-2026) by Disease Type, Indication, Treatment Type, End Users, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 189 Pages
  • June 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5410407
The Global Castleman Disease Treatment Market is estimated to be USD 134.9 Mn in 2021 and is expected to reach USD 159.83 Mn by 2026, growing at a CAGR of 13.2%.



Market Dynamics

The factor leading to the growth of the Castleman disease treatment market is increasing the number of weaker immune systems due to changing lifestyles and unhealthy eating habits. The growing prevalence of AIDS is also contributing to the growth of the Castleman disease treatment market. In addition, increasing government support and initiative for the promotion and production of orphan drugs and granting premium pricing of these drugs is creating opportunities for the growth of the global Castleman disease market.

However, some side effects such as increased blood sugar, mood swings, increased risk of infections, weight gain, damage to nearby organs during the surgery are anticipated to affect the growth of the global Castleman disease treatment market.

Market Segmentation

The Global Castleman Disease Treatment Market is segmented further based on Disease Type, Indication, Treatment Type, End Users, and Geography.

By Disease Type, the market is classified into multicentric castleman disease and Unicentric Castleman Disease. Amongst the two, the Multicentric Castleman Disease segment is estimated to hold the highest market share during the forecast period.

By Indication, the market is classified as Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor, Giant Benign Lymphoma, Giant Lymph Node Hyperplasia, and Hamartoma of the Lyphatics. Amongst all, the Angiofollicular Lymph Node Hyperplasia segment is estimated to hold the highest market share during the forecast period.

By Treatment Type, the market is classified as Radiation Therapy, Corticosteroid Drugs, Chemotherapy, Immunotherapy, Anti-Viral Drugs. Amongst all, the Chemotherapy segment is estimated to hold the highest market share during the forecast period.

By End User, the market is classified as Hospitals, Specialty Clinics, Ambulatory Surgical Centers, And Others. Amongst all, the Hospitals segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Amgen acquired Rodeo Therapeutics Corporation, a privately-held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of multiple tissues. - 30th March 2021
2. Pfizer Inc. has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. - 16th November 2020

Company Profiles

Some of the companies covered in this report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Co, Merck & Co. Inc., Pfizer Inc, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Castleman Disease Treatment Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Castleman Disease Treatment Market

What is the estimated value of the Global Castleman Disease Treatment Market?

The Global Castleman Disease Treatment Market was estimated to be valued at $134.9 Million in 2021.

What is the growth rate of the Global Castleman Disease Treatment Market?

The growth rate of the Global Castleman Disease Treatment Market is 3.4%, with an estimated value of $159.83 Million by 2026.

What is the forecasted size of the Global Castleman Disease Treatment Market?

The Global Castleman Disease Treatment Market is estimated to be worth $159.83 Million by 2026.

Who are the key companies in the Global Castleman Disease Treatment Market?

Key companies in the Global Castleman Disease Treatment Market include AbbVie Inc., Amgen Inc., Allergan, Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol, Myers Squibb and EUSA Pharma, Inc..

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Rising Prevalence of Castleman Disease
4.1.2 Rising Emergence of Novel Drugs
4.2 Restraints
4.2.1 Patent Expiry of Several Companies
4.2.2 High Cost of Dieses Treatment
4.3 Opportunities
4.3.1 Rising awareness about the treatment
4.3.2 Increasing Research and Development Activities
4.4 Challenges
4.4.1 Lack of Expertise and Insufficient Knowledge About Disease
4.4.2 Unwanted Side Effects of Treatments
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Castleman Disease Treatment Market, By Disease Type
6.1 Introduction
6.2 Multicentric Castleman Disease
6.2.1 Multicentric Without POEMS Syndrome
6.2.2 Multicentric With POEMS Syndrome With Osteosclerotic Lesions
6.2.3 Multicentric With POEMS Syndrome Without Osteosclerotic Lesions
6.3 Unicentric Castleman Disease
7 Global Castleman Disease Treatment Market, By Indication
7.1 Introduction
7.2 Angiofollicular Lymph Node Hyperplasia
7.3 Angiomatous Lymphoid
7.4 Castleman Tumor
7.5 Giant Benign Lymphoma
7.6 Giant Lymph Node Hyperplasia
7.7 Hamartoma Of The Lyphatics
8 Global Castleman Disease Treatment Market, By Treatment Type
8.1 Introduction
8.2 Radiation Therapy
8.3 Corticosteroid Drugs
8.4 Chemotherapy
8.5 Immunotherapy
8.6 Anti-Viral Drugs
9 Global Castleman Disease Treatment Market, By End Users
9.1 Introduction
9.2 Hospitals
9.3 Specialty Clinics
9.4 Ambulatory Surgical Centers
9.5 Others
10 Global Castleman Disease Treatment Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Chile
10.3.4 Colombia
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Netherlands
10.4.7 Sweden
10.4.8 Russia
10.4.9 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Sri Lanka
10.5.9 Thailand
10.5.10 Rest of APAC
10.6 Middle-East and Africa
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates
11 Competitive Landscape
11.1 Competitive Quadrant
11.2 Market Share Analysis
11.3 Strategic Initiatives
11.3.1 M&A and Investments
11.3.2 Partnerships and Collaborations
11.3.3 Product Developments and Improvements
12 Company Profiles
12.1 AbbVie Inc.
12.2 Amgen Inc.
12.3 Allergan, Inc.
12.4 AstraZeneca plc
12.5 Bayer AG
12.6 Boehringer Ingelheim GmbH
12.7 Bristol-Myers Squibb
12.8 Cardinal Health
12.9 EUSA Pharma, Inc.
12.10 F. Hoffmann-La Roche Ltd.
12.11 Gilead Sciences, Inc.
12.12 GlaxoSmithKline PLC
12.13 Hospira, Inc.
12.14 Incyte Corporation
12.15 Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
12.16 Jazz Pharmaceuticals, Inc
12.17 LGM Pharma
12.18 Merck & Co, Inc.
12.19 Novartis AG
12.20 NPS Pharmaceuticals, Inc.
12.21 Octapharma AG
12.22 Pfizer, Inc.
12.23 Relypsa, Inc.
12.24 Sanofi S.A.
12.25 Sun Pharmaceutical Industries Ltd
12.26 Santa Cruz Biotechnology, Inc
12.27 Senhwa Biosciences
12.28 Teva Pharmaceutical Industries Ltd.
12.29 Triveni Interchem Private Limited
12.30 Viatris
13 Appendix
13.1 Questionnaire

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Allergan, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cardinal Health
  • EUSA Pharma, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hospira, Inc.
  • Incyte Corporation
  • Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
  • Jazz Pharmaceuticals, Inc
  • LGM Pharma
  • Merck & Co, Inc.
  • Novartis AG
  • NPS Pharmaceuticals, Inc.
  • Octapharma AG
  • Pfizer, Inc.
  • Relypsa, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd
  • Santa Cruz Biotechnology, Inc
  • Senhwa Biosciences
  • Teva Pharmaceutical Industries Ltd.
  • Triveni Interchem Private Limited
  • Viatris